Here, IFNγ, PMA/ionomycin, and sCD40L increased the metabolic activities of the CLL cells by 47%, 24%, and 14%, respectively (Fig. 1a). This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.